Ruiyun Jiang
About
Ruiyun Jiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Ruiyun Jiang has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Ruiyun Jiang's work include Renal cell carcinoma treatment (4 papers), Colorectal Cancer Screening and Detection (4 papers) and Genetic factors in colorectal cancer (4 papers). Ruiyun Jiang is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Colorectal Cancer Screening and Detection (4 papers) and Genetic factors in colorectal cancer (4 papers). Ruiyun Jiang collaborates with scholars based in United States, United Kingdom and France. Ruiyun Jiang's co-authors include David S. Alberts, Marı́a Elena Martı́nez, Elizabeth T. Jacobs, Allen T. Hjelmfelt, Donald E. Woodward, Richard H. Hawkins, Joseph A. Van Mullem, Stephanie A. Smith‐Warner, Elaine Lanza and Arthur Schatzkin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
In The Last Decade
Ruiyun Jiang
17 papers receiving 1.0k citations
Peers
Ruiyun Jiang
Nikolaos Malamos Greece
Ivana Teodorović Serbia
Sang-Chul Lee South Korea
Peter Mueller United States
Núria Pardo Spain
N. Hoepffner Germany
Yanjun Xu China
Ian White Israel
Byung Sik Kim South Korea
Christopher J. Peters United Kingdom
Citations per year, relative to Ruiyun Jiang Ruiyun Jiang (= 1×)
peers
Nikolaos Malamos
Countries citing papers authored by Ruiyun Jiang
Since
Specialization
Citations
This map shows the geographic impact of Ruiyun Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiyun Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiyun Jiang more than expected).
Fields of papers citing papers by Ruiyun Jiang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ruiyun Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiyun Jiang. The network helps show where Ruiyun Jiang may publish in the future.
Co-authorship network of co-authors of Ruiyun Jiang
This figure shows the co-authorship network connecting the top 25 collaborators of Ruiyun Jiang. A scholar is included among the top collaborators of Ruiyun Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiyun Jiang. Ruiyun Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Galsky, Matthew D., Michiel S. van der Heijden, Thomas Powles, et al.. (2025). Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. European Urology. 88(4). 325–330.
2.
Choueiri, Toni K., Bernard Escudier, David F. McDermott, et al.. (2025). Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.. Journal of Clinical Oncology. 43(16_suppl). 4505–4505.
3.
Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2025). RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).. Journal of Clinical Oncology. 43(16_suppl). 9525–9525.
4.
Jiang, Ruiyun, et al.. (2024). A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9619–TPS9619.
5.
Tannir, Nizar M., Bernard Escudier, David F. McDermott, et al.. (2024). Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.. Journal of Clinical Oncology. 42(4_suppl). 363–363.
6.
Rini, Brian I., Sabina Signoretti, Toni K. Choueiri, et al.. (2022). Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(12). e005445–e005445.
7.
Carril-Ajuria, Lucía, Robert J. Motzer, Nizar M. Tannir, et al.. (2022). Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.. Journal of Clinical Oncology. 40(16_suppl). 4538–4538.
8.
Schjesvold, Fredrik, Meletios Α. Dimopoulos, Meral Beksaç, et al.. (2020). Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.. Journal of Clinical Oncology. 38(15_suppl). e20562–e20562.
9.
Dimopoulos, Meletios Α., Katja Weisel, Philippe Moreau, et al.. (2019). Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant. Blood. 134(Supplement_1). 3120–3120.
10.
Poynard, Thierry, Jordi Bruix, Eugene R. Schiff, et al.. (2012). Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. Journal of Hepatology. 58(3). 452–459.
11.
Melia, Michael T., Andrew J. Muir, Jonathan McCone, et al.. (2011). Racial differences in hepatitis C treatment eligibility. Hepatology. 54(1). 70–78.
12.
Martı́nez, Marı́a Elena, John A. Baron, David A. Lieberman, et al.. (2008). A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic Polypectomy. Gastroenterology. 136(3). 832–841.
13.
Robertson, Douglas J., David A. Lieberman, Sidney J. Winawer, et al.. (2008). 795 Interval Cancer After Total Colonoscopy: Results from a Pooled Analysis of Eight Studies. Gastroenterology. 134(4). A–111.
14.
Jacobs, Elizabeth T., Marı́a Elena Martı́nez, David S. Alberts, et al.. (2007). Association Between Body Size and Colorectal Adenoma Recurrence. Clinical Gastroenterology and Hepatology. 5(8). 982–990.
15.
Martı́nez, Marı́a Elena, Edward L. Giovannucci, Ruiyun Jiang, et al.. (2006). Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. International Journal of Cancer. 119(6). 1440–1446.
16.
Jacobs, Elizabeth T., Elaine Lanza, David S. Alberts, et al.. (2006). Fiber, sex, and colorectal adenoma: results of a pooled analysis. American Journal of Clinical Nutrition. 83(2). 343–349.
17.
Martı́nez, Marı́a Elena, Patricia A. Thompson, Elizabeth T. Jacobs, et al.. (2006). Dietary Factors and Biomarkers Involved in the Methylenetetrahydrofolate Reductase Genotype–Colorectal Adenoma Pathway. Gastroenterology. 131(6). 1706–1716.
18.
Einspahr, Janine G., Marı́a Elena Martı́nez, Ruiyun Jiang, et al.. (2006). Associations of Ki-ras Proto-oncogene Mutation and p53 Gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. Cancer Epidemiology Biomarkers & Prevention. 15(8). 1443–1450.
19.
Martínez, María, Mary E. Reid, Ruiyun Jiang, Janine G. Einspahr, & David S. Alberts. (2004). Accuracy of self-reported smoking status among participants in a chemoprevention trial. Preventive Medicine. 38(4). 492–497.
20.
Woodward, Donald E., et al.. (2003). Runoff Curve Number Method: Examination of the Initial Abstraction Ratio. 1–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nikolaos Malamos Breakdown of academic impact, for papers by Ivana Teodorović Breakdown of academic impact, for papers by Sang-Chul Lee Breakdown of academic impact, for papers by Peter Mueller Breakdown of academic impact, for papers by Núria Pardo Breakdown of academic impact, for papers by N. Hoepffner Breakdown of academic impact, for papers by Yanjun Xu Breakdown of academic impact, for papers by Ian White Breakdown of academic impact, for papers by Byung Sik Kim Breakdown of academic impact, for papers by Christopher J. Peters